Carisma Therapeutics, Inc. (CARM)

Market Cap	1.78M
Revenue (ttm)	10.77M
Net Income (ttm)	-49.38M
Shares Out	41.79M
EPS (ttm)	-1.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	811,221
Average Volume	2,508,448
Open	0.0380
Previous Close	0.0352
Day's Range	0.0360 - 0.0500
52-Week Range	0.0261 - 1.2700
Beta	3.81
RSI	23.52
Earnings Date	Nov 7, 2025

About Carisma Therapeutics

Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidate includes CT-2401, which is in preclinical trail for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 46
• Stock Exchange: OTCMKTS
• Ticker Symbol: CARM

Financial Performance

In 2024, Carisma Therapeutics's revenue was $19.63 million, an increase of 31.59% compared to the previous year's $14.92 million. Losses were -$60.48 million, -30.39% less than in 2023.